Name (Synonyms) | Correlation | |
---|---|---|
drug270 | Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment Wiki | 1.00 |
drug1043 | washed microbiota transplantation Wiki | 1.00 |
drug788 | Standard treatment Wiki | 0.58 |
drug1003 | placebo Wiki | 0.38 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.12 |
D007239 | Infection NIH | 0.08 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Submitted by Mahmoud Elkazzaz Assessment the Activity Value of 13- cis-Retinoic Acid(Isotretinoin) in the Treatment of COVID-19 Mahmoud ELkazzaz(a),Tamer Haydara(b),Mohamed Abdelaal(c),Ahmed M. Kabel(d),Abedelaziz Elsayed (e)Hesham Attia(f) 1. PI's,Department of chemistry and biochemistry, Faculty of Science, Damietta University,GOEIC,Egypt. 2. SI's,Department of Internal Medicine,Faculty of Medicine, Kafrelsheikh University, Egypt 3. SI's,Department of Cardiothoracic Surgery,Faculty of Medicine, Kafrelsheikh University, Egypt 4. SI's,Department of Clinical Pharmacy, Faculty of Pharmacy, Taif University, Taif, Saudi Arabia. 5. SI's, Department of Pharmaceutical Biotechnology, Faculty of Pharmacy,Tanta University,Egypt. 6. SI's,Department of Immunology and Parasitology,Faculty of Science,Cairo university,Egypt. Roles of the Investigators according to ClinicalTrials.gov: 1. Principal Investigator(PI's): is the Corresponding Author and the Innovative of Protocol Ideas who is responsible for replying any questions related to the Protocol Ideas and Mechanisms and have rights to discuss or publish Trial Results after the Trial is completed as the First Author followed by Sub Investigators as Second, Middle, and Last Authors on future published results. 2. Sub Investigators(SI's): are the Adopters of the Protocol Most of them are experienced and professional Human Doctors and Pharmacists who are familiar with respiratory diseases and drugs interactions and they able to make study-related decisions regarding the diagnosis and treatment of the disease or condition under investigation and they are aware of how to deal with patients, especially patients with the emerging coronavirus, because it is a serious threat and rapidly spreading virus and Also, to make sure there aren't any medication interaction, errors and misuse and they are responsible for applying the methodology section of the Protocol In addition to following upThe Infected Patients and recording Drug side effects ________________________________________________________________________________________ ______________________________________________________ Brief Summary: The COVID-19 pandemic caused by SARS-COV-2 has infected over 2,000,000 people causing over 150,000 deaths.Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 and for which there are currently no approved treatments. Here, the principal investigator reports according to previous studies and research findings that retinoic acid could strongly affect both inflammation and viral entry in severe acute respiratory syndrome (SARS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection via modulating and reducing cytokine storm factors (IL- 6,IL-1,IL-10 and tumor necrosis factors alpha ) which are over expressed in COVID 2019 infection and contribute to disease progression, poor outcomes and poor survival in patients infected with severe acute respiratory syndrome(SARS-CoV-2) and also, via blocking viral entry by inhibition factor which induce Serine protease 2 expression rather than inhibition of ACE2 ,AT1 protein and Ang II-mediated intracellular calcium release pathway which is responsible for SARS-CoV-2 cell fusion and entry as opposed to medications that upregulate ACE-2 receptors might increase the risk of infection and subsequent complications.Retinoic acid which induce FOXP3 and CD8+,CD4+,CD25+,FOXP3+ Tregs which their absence during acute infection alters the ability of the host to limit tissue damage. and T cells which were dramatically reduced in COVID-19 patients to exert its antiviral and anti-inflammatory effect protecting lung cells and neural cells from the inflammatory and the destructive effect of IL-6. In addition to inducing retinoic acid inducible gene-1 (RIG-1) and endosomal toll-like receptor 3 (TLR3) as pathogen-associated molecular patterns. This recognition resulted in the formation of type-1 interferon (IFN1). As an evasion mechanism, virus synthesize proteins that hinder the production of IFN type1 in COVID 2019 . In adition to its anti-platelet and fibrinolytic activities protecting patients infected with covid 2019 infection from widespread blood clots. Keywords: COVID 2019 , Retinoic acid, Endosomal toll-like receptor 3,T Cells, IFN type1, AT1,ACE2,TMPRSS2,RIG-1.
Description: Proportion of lung injury score decreased or increased after treatment
Measure: lung injury score Time: at 7and 14 daysDescription: lymphocyte counts
Measure: Absolute lymphocyte counts Time: at day 7 and 14 after randimizationDescription: Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon
Measure: Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon Time: at day 7 and 14 after randimizationDescription: Serum level of COVID19 RNA
Measure: Serum level of COVID19 RNA Time: at day 7 and 14Description: died
Measure: All cause mortality rate Time: at day 7 and 14Description: ventilation free days
Measure: Ventilation free days Time: at 14 daysDescription: ICU free days
Measure: ICU free days Time: at 14 daysDescription: less than 250 ng/mL, or less than 0.4 mcg/mL of blood sample
Measure: d-dimers Time: at 3-5daysDescription: (if pos. at baseline)
Measure: Time to first negative SARS-CoV-2 PCR in NP swap Time: within 14 days